A venture capital firm based in Solana Beach, CA provides seed funding to very early stage companies and also invests in Series A financing rounds. The firm is actively seeking investments and will allocate around $500K – 2.5 M, with preferred financing structures being equity and convertible preferred equity. Although the firm has invested in companies outside the USA, the firm focuses its investments on USA-based companies.

In the life sciences space, the firm is primarily interested in healthcare IT/digital health technologies and services as well as medical devices and diagnostic tools that have a tech-enabled component. The firm is open to devices of all FDA regulatory pathways including 510k and PMA. Products that have not begun clinical trials will most likely be considered too early, so these devices should at least be undergoing clinical trials. The firm is not interested in companies in the therapeutics sector.

The firm seeks to work with privately owned companies with an experienced management team that is dedicated full-time. CEOs with experience founding successful start-up companies is a strong plus. The firm can act as either a lead or co-investor in financing rounds, and will generally seek a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in New York City is focused on companies in the healthcare field with a preference for Medtech, Healthcare IT, and Consumer Health. The firm is currently investing out of their second fund, and hopes to make 2-3 investments out of it this coming year. The firm invests in all stages of companies, from Series A to Series G.

The firm considers themselves opportunistic within the healthcare field when looking for investments. The firm focuses on three major categories: Medtech (Devices and Diagnostics), Healthcare IT, and Consumer Health and is opportunistic within all three. The firm tends to prefer investments within the medtech space, a space they’re more experienced in. While opportunistic, the firm prefers opportunities in the hearing, vision, heart failure, neuromodulation, and diabetes due to previous experience in these sectors. Regarding Healthcare IT interests, the firm prefers opportunities targeted towards large audiences such as healthcare systems or large patient populations.

The firm wants to see a strong CEO and Board when making investments. The firm invests in both pre-revenue and post-revenue companies. The firm typically invests alongside a syndicate of investors, but is looking to lead or co-lead more investments in their second fund. When leading or co-leading the firm requires a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An asset management group based in China operates a USD fund of $50 million that invests in healthcare and technology startups. Typical equity investment size ranges from US$0.5-2 million in Pre-A to Series A stage companies. The firm is open to either leading or following in a syndicated round. The firm expects to make 10+ deals in the next 12 months and can invest globally with a focus on the US and Canada.

The firm considers broadly across healthcare industries including innovative drugs, medical devices, and healthcare IT products. The firm has an increased interest in medical devices and imaging technology. The firm prefers companies that have completed a prototype and obtained FDA clearance or are ready for FDA submission. The firm is agnostic to indication areas.

The firm is looking for experienced management teams. The firm can leverage its innovation center to assist with commercialization in the China market. The firm my request distribution rights and board representation post investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A large conglomerate headquartered in China has a primary business in single-use medical devices, with a wide range of product lines in consumables, orthopedic materials, and blood purification. The group also has subsidiaries in biopharmaceutical, healthcare services, finance, and real estate. The firm is actively expanding its healthcare business in China. The group is seeking product-based collaboration opportunities with early stage medical device businesses overseas, primarily through joint venture or incubation. Typical investments range from RMB 1-30 million (US$0.1 – 4.4 M), while there is no set upper limit. The firm would also consider in-licensing opportunities.

The firm is focusing on medical devices with an elevated interest in coronary stent, vascular ultrasound, endoscope, and surgical devices. The firm is also interested in medical technologies that are complimentary to its product line, which includes: i) consumables (infusion sets, syringes, medical needles, blood bags, pre-filled syringes, blood sampling products, and other consumables); ii) orthopedic materials and iii) blood purification consumables and equipment. The group prefers products that have received FDA clearance/approval or at early commercial stage, while it is also open to projects that are pending an FDA decision. The group would also consider biopharmaceutical assets in kidney diseases.

The firm is seeking strong management teams with mature products that have received or are close to receiving regulatory approval.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com